Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABCLNASDAQ:GLPGNASDAQ:HRMYNASDAQ:INSM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$3.63-6.9%$4.59$3.62▼$8.05$1.06B0.361.37 million shs1.83 million shsGLPGGalapagos$28.63-0.5%$33.51$28.33▼$45.21$1.89B0.24129,271 shs167,894 shsHRMYHarmony Biosciences$28.93-1.0%$31.58$18.61▼$39.26$1.64B0.73373,674 shs313,047 shsINSMInsmed$24.92-3.4%$27.24$18.08▼$32.00$3.70B0.921.77 million shs1.21 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-1.76%-0.51%-14.85%-26.69%-42.05%GLPGGalapagos-2.31%-1.54%-11.96%-23.30%-25.02%HRMYHarmony Biosciences+1.32%+0.14%-10.34%-5.83%-7.97%INSMInsmed+2.14%-1.41%-4.41%-6.92%+37.00%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics1.7684 of 5 stars3.51.00.00.01.03.30.6GLPGGalapagos0.4758 of 5 stars2.01.00.00.02.20.01.3HRMYHarmony Biosciences4.2552 of 5 stars3.30.00.00.03.54.24.4INSMInsmed3.9776 of 5 stars4.51.00.04.51.90.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics3.00Buy$15.86336.84% UpsideGLPGGalapagos2.00Hold$34.5020.50% UpsideHRMYHarmony Biosciences2.50Moderate Buy$40.6340.43% UpsideINSMInsmed3.00Buy$44.9280.24% UpsideCurrent Analyst RatingsLatest HRMY, GLPG, INSM, and ABCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024INSMInsmedTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$48.004/22/2024GLPGGalapagosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$38.00 ➝ $38.004/12/2024HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$49.004/11/2024INSMInsmedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $40.004/9/2024HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.004/1/2024INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.003/28/2024GLPGGalapagosBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$41.00 ➝ $31.003/28/2024HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$49.003/7/2024GLPGGalapagosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$38.002/27/2024HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.002/27/2024INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$38.03M27.95N/AN/A$3.97 per share0.91GLPGGalapagos$259.40M7.27$0.63 per share45.23$45.92 per share0.62HRMYHarmony Biosciences$582.02M2.82$2.62 per share11.06$7.97 per share3.63INSMInsmed$305.21M12.13N/AN/A($2.32) per share-10.74Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$146.40M-$0.52N/AN/AN/A-384.99%-12.36%-9.70%5/7/2024 (Confirmed)GLPGGalapagos$229.12M-$2.29N/A477.17N/A-26.25%-2.60%-1.46%5/2/2024 (Estimated)HRMYHarmony Biosciences$128.85M$2.1213.657.340.4022.16%27.49%16.83%4/30/2024 (Confirmed)INSMInsmed-$749.57M-$5.34N/AN/AN/A-245.59%N/A-53.34%5/2/2024 (Estimated)Latest HRMY, GLPG, INSM, and ABCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AABCLAbCellera Biologics-$0.16N/A+$0.16N/AN/AN/A 4/30/2024N/AHRMYHarmony Biosciences$0.64N/A-$0.64N/AN/AN/A 2/22/2024Q4 2023HRMYHarmony Biosciences$0.74$0.45-$0.29$0.45$168.90 million$168.40 million 2/22/202412/31/2023INSMInsmed-$1.13-$1.28-$0.15-$1.28$82.15 million$83.70 million 2/20/2024Q4 2023ABCLAbCellera Biologics-$0.14-$0.17-$0.03-$0.17$9.58 million$9.18 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A7.337.33GLPGGalapagosN/A9.028.84HRMYHarmony Biosciences0.382.752.72INSMInsmedN/A4.123.75OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%GLPGGalapagos32.46%HRMYHarmony Biosciences86.23%INSMInsmedN/AInsider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics32.45%GLPGGalapagos2.91%HRMYHarmony Biosciences30.80%INSMInsmed4.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics586292.78 million197.77 millionOptionableGLPGGalapagos1,12365.90 million63.98 millionOptionableHRMYHarmony Biosciences24656.79 million39.30 millionOptionableINSMInsmed373148.55 million141.72 millionOptionableHRMY, GLPG, INSM, and ABCL HeadlinesSourceHeadlineInsmed shares upgraded on growth potentialinvesting.com - April 25 at 5:59 PMInsmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024prnewswire.com - April 25 at 8:00 AMInsmed (NASDAQ:INSM) Shares Gap Up to $24.11americanbankingnews.com - April 25 at 5:44 AMInsmed (NASDAQ:INSM) Receives New Coverage from Analysts at Truist Financialamericanbankingnews.com - April 24 at 4:44 AMTruist Securities Initiates Coverage of Insmed (INSM) with Buy Recommendationmsn.com - April 24 at 3:19 AMInsmed gets grant for treatment of gram-positive pulmonary bacterial infectionspharmaceutical-technology.com - April 23 at 5:18 PMTruist Financial Begins Coverage on Insmed (NASDAQ:INSM)marketbeat.com - April 23 at 7:15 AMInsmed (NASDAQ:INSM) Sees Large Volume Increasemarketbeat.com - April 22 at 1:31 PMActress Jane Seymour on the Effects of “Unseenism” and the #1 Way To Fight It: “Health Is Everything”msn.com - April 20 at 10:28 AMKnights of Columbus Asset Advisors LLC Raises Stock Position in Insmed Incorporated (NASDAQ:INSM)marketbeat.com - April 19 at 1:38 PMAnalysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)markets.businessinsider.com - April 16 at 8:04 PMHead to Head Survey: Daré Bioscience (NASDAQ:DARE) versus Insmed (NASDAQ:INSM)americanbankingnews.com - April 16 at 1:44 AMBarclays Increases Insmed (NASDAQ:INSM) Price Target to $40.00marketbeat.com - April 11 at 10:33 AMWhat Makes Insmed (INSM) a Lucrative Investment?finance.yahoo.com - April 10 at 2:02 PMPeregrine Capital Management LLC Reduces Stock Position in Insmed Incorporated (NASDAQ:INSM)marketbeat.com - April 10 at 9:48 AMInsmed Incorporatedcnn.com - April 6 at 9:42 PMInsmed Incorporated: Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)finanznachrichten.de - April 5 at 1:37 PMInsmed's (INSM) Overweight Rating Reiterated at Wells Fargo & Companymarketbeat.com - April 1 at 12:23 PM5 Top Companies Hiring in New Jerseybiospace.com - March 28 at 12:44 PMInsmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conferencefinance.yahoo.com - March 27 at 4:22 PMVanguard Group Inc. Raises Holdings in Insmed Incorporated (NASDAQ:INSM)marketbeat.com - March 27 at 4:26 AMStrong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed’s Brensocatibmarkets.businessinsider.com - March 19 at 10:21 AMINSM Apr 2024 25.000 putfinance.yahoo.com - March 17 at 10:36 AMCrinetics Pharmaceuticals Earns ‘Buy’ Rating on Clinical Success and Market Expansion Potentialmarkets.businessinsider.com - March 15 at 7:18 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbCellera BiologicsNASDAQ:ABCLAbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.GalapagosNASDAQ:GLPGGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Harmony BiosciencesNASDAQ:HRMYHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.InsmedNASDAQ:INSMInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.